E16: Comprehensive Cost Implications of Commercially Available Noninvasive Colorectal Cancer Screening Modalities

In this episode, Dr Dante Yeh is joined by Casey Allen, MD, from the Institute of Surgery, Division of Surgical Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania. They discuss Dr Allen’s recent study, which found that widespread adoption of the fecal immunochemical test for noninvasive colorectal cancer screening could lead to substantial cost savings. This carries major value implications for a large population health system.

Disclosure Information: Dr Allen has nothing to disclose. Dr Yeh receives author royalties from UpToDate, advisory panel/training honoraria from Takeda Pharmaceuticals, and advisory panel honoraria from Baxter, Eli Lilly, and Fresenius Kabi.

To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date. Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more.

Allen, Casey J MD; Bloom, Nathan BS; Rothka, Michael BS; Rao, Pavan MD; Wagner, Patrick L MD, FACS; Bartlett, David L MD, FACS; Farah, Katie MD; Chalikonda, Sricharan MD, FACS. Comprehensive Cost Implications of Commercially Available Noninvasive Colorectal Cancer Screening Modalities. Journal of the American College of Surgeons 237(3):p 465-472, September 2023. | DOI: 10.1097/XCS.0000000000000768 

#JACSOperativeWord